Inflarx N V Revenue Growth Rates (IFRX), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Inflarx N V  (NASDAQ: IFRX)
 

IFRX's Revenue Growth by Quarter and Year

Inflarx N V's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

IFRX Revenue (in millions $) FY 2025 FY 2024 FY 2023 FY 2022
4th Quarter December 0.03
3rd Quarter September 0.00
2nd Quarter June 0.04
1st Quarter March 0.00
FY 0.07





IFRX Revenue fourth quarter 2025 Y/Y Growth Comment
Inflarx N V reported Revenue surge of 228.51% year on year in the fourth quarter 2025, to $ 0.03 millions, this is lower than Inflarx N V's recent average Revenue surge of 553.13%.

Looking into fourth quarter 2025 results within Major Pharmaceutical Preparations industry 32 other companies have achieved higher Revenue growth. While Inflarx N V' s Revenue doubling of 228.51% ranks overall at the positon no. 213 in the fourth quarter 2025.


IFRX Revenue ( Y/Y Growth %) 2025
 2024 2023 2022
4th Quarter December 228.51 % - - -
3rd Quarter September - - - -
2nd Quarter June - - - -
1st Quarter March - - - -
FY   -8.94 % - - -

Financial Statements
Inflarx N V's fourth quarter 2025 Revenue $ 0.03 millions IFRX's Income Statement
Inflarx N V's fourth quarter 2024 Revenue $ 0.01 millions Quarterly IFRX's Income Statement


IFRX Revenue (Quarter on Quarter Growth %)

 2025
 2024 2023 2022
4th Quarter December - -85.71 % - -
3rd Quarter September - - - -
2nd Quarter June - - - -
1st Quarter March - - - -
FY (Year on Year)   -8.94 % - - -


Back to IFRX Growth rate Comparisons >> Back to IFRX Growth rate Comparisons >>


Revenue fourth quarter 2025 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #33
Healthcare Sector #60
Overall #213

Revenue Y/Y Growth Statistics
High Average Low
553.13 % 553.13 % 553.13 %
 
Revenue fourth quarter 2025 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #33
Healthcare Sector #60
Overall #213
Revenue Y/Y Growth Statistics
High Average Low
553.13 % 553.13 % 553.13 %
 

Revenue by Quarter for the Fiscal Years 2022, 2023, 2024, 2025

Inflarx N V's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


IFRX's IV. Quarter Q/Q Revenue Comment


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


IFRX's IV. Quarter Q/Q Revenue Comment


Inflarx N V's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Dec 31 2024)		 12 Months Ending
(Dec 31 2023)		 12 Months Ending
(Dec 31 2022)		 12 Months Ending
(Dec 31 2020)
Cumulative Revenue 12 Months Ending $ 0.03 $ 0.18 $ 0.07 $ 0.00 $ 0.00
Y / Y Revenue Growth (TTM) -81.69 % 153.87 % - - -
Year on Year Revenue Growth Overall Ranking # 3802 # 0 # 0 # 0 # 0
Seqeuential Revenue Change (TTM) -81.69 % 153.87 % - - -
Seq. Revenue Growth (TTM) Overall Ranking # 3802 # 0 # 0 # 0 # 0


Cumulative Revenue growth Comment
For the 12 months ended Dec 31 2025 Inflarx N V reported a sharp drop in Revenue by -81.69% year on year, to $0 millions, compare to the 153.87% growth at Dec 31 2024.

In the Healthcare sector 507 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 3802.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 177
Healthcare Sector # 508
Overall # 3802

Revenue TTM Y/Y Growth Statistics
High Average Low
-53.51 %
 -53.51 %
-53.51 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 177
Sector # 508
S&P 500 # 3802
Cumulative Revenue growth Comment
For the 12 months ended Dec 31 2025 Inflarx N V reported a sharp drop in Revenue by -81.69% year on year, to $0 millions, compare to the 153.87% growth at Dec 31 2024.

In the Healthcare sector 507 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 3802.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 177
Healthcare Sector # 508
Overall # 3802

Revenue TTM Y/Y Growth Statistics
High Average Low
-53.51 %
-53.51 %
-53.51 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 177
Sector # 508
S&P 500 # 3802




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
IFRX's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue sharp drop for the quarter ending Dec 31 2025 within Healthcare SectorY/Y Change %Revenue for the quarter ending Dec 31 2025
Aspira Women s Health inc 385.61%$ 385.609 millions
Intercure Ltd 318.38%$ 318.385 millions
Vireo Growth Inc.317.81%$ 317.813 millions
Cormedix Inc 312.10%$ 312.097 millions
Galapagos Nv303.50%$ 303.502 millions
Insmed Inc287.83%$ 287.825 millions
Tscan Therapeutics Inc 286.02%$ 286.015 millions
Beam Therapeutics Inc 279.52%$ 279.516 millions
Meiragtx Holdings Plc252.33%$ 252.333 millions
Star Equity Holdings Inc 232.22%$ 232.220 millions
Ethema Health Corporation 228.03%$ 228.030 millions
Foghorn Therapeutics Inc 223.77%$ 223.775 millions
Madrigal Pharmaceuticals Inc 210.77%$ 210.766 millions
Biocryst Pharmaceuticals Inc 209.09%$ 209.087 millions
Prenetics Global Limited201.94%$ 201.941 millions
Prokidney Corp 196.05%$ 196.053 millions
Mesoblast Limited191.39%$ 191.393 millions
Northwest Biotherapeutics Inc190.91%$ 190.909 millions
Zevra Therapeutics Inc 183.36%$ 183.360 millions
Spero Therapeutics Inc 174.51%$ 174.508 millions
Taysha Gene Therapies Inc 171.27%$ 171.266 millions
Compugen Ltd161.14%$ 161.140 millions
Nyxoah Sa156.29%$ 156.287 millions
Nuo Therapeutics Inc 153.57%$ 153.570 millions
Anaptysbio Inc 151.08%$ 151.082 millions
Theravance Biopharma inc 144.70%$ 144.700 millions
Voyager Therapeutics Inc 144.28%$ 144.282 millions
Esperion Therapeutics Inc 143.73%$ 143.725 millions
Foxo Technologies Inc 141.54%$ 141.542 millions
Volitionrx Limited133.25%$ 133.247 millions


About Inflarx N V Revenue Growth Rates (IFRX), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Inflarx N V (CIK 1708688).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001213900-26-032065
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Inflarx N V’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.